What is the primary revenue source for Siren Therapeutics (SRXH)?

According to the latest financial reports, the company's revenue is driven by its core business segments and operational services. You can explore the exact breakdown and proportions of each revenue stream using the interactive charts on this page.

How can I visualize and analyze SRXH's financial statements?

gkcal provides interactive Sankey diagrams and profit waterfall charts that map out Siren Therapeutics's total revenue, cost of goods sold, operating expenses, and net income, making it easy to understand their business model and cash flow at a glance.

How Siren Therapeutics Makes Money: SRXH Revenue Breakdown (2026)

Operations

Where did the money come from, and where was it spent?

Watch

Revenue and operating profit grew, but the material margin decline warrants attention.

The largest revenue segment accounts for 81.22% of revenue, indicating concentration.

Operating margin declined by 230.56 percentage points year over year.

Revenue: USD 9.64M
Largest revenue segment share (UNITED STATES): 81.22%
Selling, general and administrative: USD 12.04M
Cost of revenue: USD 6.41M

View calculation evidence

YoY periods: 9M 2026 compared with 9M 2025

Source metrics

RevenueNet sales · RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenueCost of goods sold · CostOfGoodsAndServicesSold
Selling, general and administrativeSelling, general and administrative · SellingGeneralAndAdministrativeExpense
Largest revenue segment share (UNITED STATES)UNITED STATES · segment_value / revenue * 100
Operating marginLoss from continuing operations · operating_income / revenue * 100

Assets

Where is the money tied up, and how is the company financed?

Neutral

Liabilities and shareholder equity jointly fund the asset base, with a broadly stable mix.

Cash and cash equivalents: USD 35.19M
Accounts receivable: USD 3.63M
Inventory: USD 2.61M
Total liabilities: USD 2.37M
Shareholder equity: USD 142.99M

View calculation evidence

YoY periods: 9M 2026 compared with 9M 2025

Source metrics

Shareholder equityTotal stockholders’ equity · StockholdersEquity
Total liabilitiesTotal liabilities · Liabilities
InventoryInventories, net · InventoryNet
Accounts receivableAccounts receivable, net · AccountsReceivableNetCurrent
Cash and cash equivalentsCash and cash equivalents · CashAndCashEquivalentsAtCarryingValue

Cash

Did accounting profit ultimately turn into cash?

Insufficient data

Current data explains this period's structure but is insufficient for a year-over-year conclusion.

View calculation evidence

YoY periods: 9M 2026 compared with 9M 2025

Some conclusions lack complete source metrics and should be interpreted cautiously.

Capital expenditure data is missing, so free cash flow cannot be calculated.

Shareholders

Did the money earned actually make its way back to shareholders?

Insufficient data

Current data explains this period's structure but is insufficient for a year-over-year conclusion.

View calculation evidence

YoY periods: 9M 2026 compared with 9M 2025

Share repurchase data is missing, making net shareholder return incomplete.

Diluted share count is missing, so dilution cannot be assessed against buybacks.

Financial Insights

Please select a report to view

Where did the money come from, and where was it spent?

Where is the money tied up, and how is the company financed?

Did accounting profit ultimately turn into cash?

Did the money earned actually make its way back to shareholders?